share_log

Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32

Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32

Aegis Capital以买入评级开始对AvenueTherapeutics进行报道,宣布目标股价为32美元
Benzinga ·  2023/04/03 13:32

Aegis Capital analyst David Bouchey initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $32.

Aegis Capital分析师戴维·布奇以买入评级开始对Avenue Therapeutics(纳斯达克股票代码:ATXI)进行报道,并宣布目标价为32美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发